

Steven Baxter Marston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/504626/publications.pdf>

Version: 2024-02-01

121
papers

4,503
citations

66234

42
h-index

114278

63
g-index

124
all docs

124
docs citations

124
times ranked

3402
citing authors

#	ARTICLE	IF	CITATIONS
1	Titin-truncating mutations associated with dilated cardiomyopathy alter length-dependent activation and its modulation via phosphorylation. <i>Cardiovascular Research</i> , 2022, 118, 241-253.	1.8	16
2	Modulation of cardiac thin filament structure by phosphorylated troponin-I analyzed by protein-protein docking and molecular dynamics simulation. <i>Archives of Biochemistry and Biophysics</i> , 2022, 725, 109282.	1.4	11
3	Force Measurements From Myofibril to Filament. <i>Frontiers in Physiology</i> , 2021, 12, 817036.	1.3	2
4	Troponin structure and function: a view of recent progress. <i>Journal of Muscle Research and Cell Motility</i> , 2020, 41, 71-89.	0.9	57
5	Donor hearts in the Sydney Heart Bank: reliable control but is it â€œnormalâ€™ heart?. <i>Biophysical Reviews</i> , 2020, 12, 799-803.	1.5	2
6	Distinct hypertrophic cardiomyopathy genotypes result in convergent sarcomeric proteoform profiles revealed by top-down proteomics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24691-24700.	3.3	67
7	Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9599.	1.8	36
8	Pressure Overload Is Associated With Low Levels of Troponin I and Myosin Binding Protein C Phosphorylation in the Hearts of Patients With Aortic Stenosis. <i>Frontiers in Physiology</i> , 2020, 11, 241.	1.3	2
9	Approaches to High-Throughput Analysis of Cardiomyocyte Contractility. <i>Frontiers in Physiology</i> , 2020, 11, 612.	1.3	16
10	The European Muscle Conference 2019 Special Issue. <i>Journal of Muscle Research and Cell Motility</i> , 2019, 40, 67-67.	0.9	0
11	Small molecule studies: the fourth wave of muscle research. <i>Journal of Muscle Research and Cell Motility</i> , 2019, 40, 69-76.	0.9	9
12	The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM. <i>Journal of General Physiology</i> , 2019, 151, 18-29.	0.9	25
13	The Molecular Defects in Ca ²⁺ Regulation due to Mutations that Cause Hypertrophic Cardiomyopathy can be Reversed by Small Molecules that Bind to Troponin. <i>Biophysical Journal</i> , 2018, 114, 37a.	0.2	2
14	Effect of Truncated Mutations in the Titin Gene on Cardiac Function. <i>Biophysical Journal</i> , 2018, 114, 498a.	0.2	0
15	Molecular Defects in Cardiac Myofilament Ca ²⁺ -Regulation Due to Cardiomyopathy-Linked Mutations Can Be Reversed by Small Molecules Binding to Troponin. <i>Frontiers in Physiology</i> , 2018, 9, 243.	1.3	19
16	The Molecular Mechanisms of Mutations in Actin and Myosin that Cause Inherited Myopathy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2020.	1.8	27
17	Obscurin variants and inherited cardiomyopathies. <i>Biophysical Reviews</i> , 2017, 9, 239-243.	1.5	25
18	Age- and strain-related aberrant Ca ²⁺ release is associated with sudden cardiac death in the ACTC E99K mouse model of hypertrophic cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 313, H1213-H1226.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Tropomyosin Must Interact Weakly with Actin to Effectively Regulate Thin Filament Function. <i>Biophysical Journal</i> , 2017, 113, 2444-2451.	0.2	18
20	Abnormal contractility in human heart myofibrils from patients with dilated cardiomyopathy due to mutations in TTN and contractile protein genes. <i>Scientific Reports</i> , 2017, 7, 14829.	1.6	40
21	Investigations into the Sarcomeric Protein and Ca ²⁺ -Regulation Abnormalities Underlying Hypertrophic Cardiomyopathy in Cats (<i>Felis catus</i>). <i>Frontiers in Physiology</i> , 2017, 8, 348.	1.3	15
22	A post-MI power struggle: adaptations in cardiac power occur at the sarcomere level alongside MyBP-C and RLC phosphorylation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H465-H475.	1.5	7
23	Why Is there a Limit to the Changes in Myofilament Ca ²⁺ -Sensitivity Associated with Myopathy Causing Mutations?. <i>Frontiers in Physiology</i> , 2016, 7, 415.	1.3	23
24	The Importance of Intrinsically Disordered Segments of Cardiac Troponin in Modulating Function by Phosphorylation and Disease-Causing Mutations. <i>Frontiers in Physiology</i> , 2016, 7, 508.	1.3	10
25	Primary Effects of HCM Mutations in Humans And Cats. <i>Biophysical Journal</i> , 2016, 110, 123a-124a.	0.2	1
26	Troponin Structure and Effects of Phosphorylation and Mutations Studied by Molecular Dynamics Simulations. <i>Biophysical Journal</i> , 2016, 110, 208a.	0.2	1
27	Molecular Mechanism of Novel Deletions in TPM3 that cause a Hypercontractile Phenotype with Congenital Muscle Stiffness. <i>Biophysical Journal</i> , 2016, 110, 14a-15a.	0.2	0
28	Troponin structure: its modulation by Ca ²⁺ and phosphorylation studied by molecular dynamics simulations. <i>Physical Chemistry Chemical Physics</i> , 2016, 18, 20691-20707.	1.3	21
29	Mutations in troponin T associated with Hypertrophic Cardiomyopathy increase Ca ²⁺ -sensitivity and suppress the modulation of Ca ²⁺ -sensitivity by troponin I phosphorylation. <i>Archives of Biochemistry and Biophysics</i> , 2016, 601, 113-120.	1.4	49
30	Instrumentation to study myofibril mechanics from static to artificial simulations of cardiac cycle. <i>MethodsX</i> , 2016, 3, 156-170.	0.7	8
31	â€(De-)sensitizationâ€™ vs. â€Uncouplingâ€™: what drives cardiomyopathies in the thin filament? Reply. <i>Cardiovascular Research</i> , 2016, 109, 187-188.	1.8	1
32	A dilated cardiomyopathy mutation blunts adrenergic response and induces contractile dysfunction under chronic angiotensin II stress. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H1936-H1946.	1.5	18
33	DCM Mutation ACTCE361G Causes Uncoupling of Myofibril Sensitivity from TnI Phosphorylation that can be Reversed by Epigallocatechin-3-Gallate. <i>Biophysical Journal</i> , 2015, 108, 292a.	0.2	0
34	Molecular Dynamics Studies on Phosphorylated and Unphosphorylated Cardiac Troponin. <i>Biophysical Journal</i> , 2015, 108, 447a.	0.2	0
35	Epigallocatechin-3-Gallate Reverses the Defects in Modulation of Ca ²⁺ -Sensitivity by Troponin I Phosphorylation Caused by Hypertrophic and Dilated Cardiomyopathy Mutations in Cardiac Muscle. <i>Biophysical Journal</i> , 2015, 108, 361a-362a.	0.2	1
36	Obscurin Mutations Cause Haploinsufficiency and are Common in Patients with Familial Dilated Cardiomyopathy (FDCM). <i>Biophysical Journal</i> , 2015, 108, 292a.	0.2	0

#	ARTICLE	IF	CITATIONS
37	OBSCN Mutations Associated with Dilated Cardiomyopathy and Haploinsufficiency. PLoS ONE, 2015, 10, e0138568.	1.1	70
38	Uncoupling of myofilament Ca ²⁺ sensitivity from troponin I phosphorylation by mutations can be reversed by epigallocatechin-3-gallate. Cardiovascular Research, 2015, 108, 99-110.	1.8	29
39	<sc><i>TPM</i></sc><i>3</i> deletions cause a hypercontractile congenital muscle stiffness phenotype. Annals of Neurology, 2015, 78, 982-994.	2.8	36
40	Important announcement: a rational nomenclature for tropomyosin variants. Journal of Muscle Research and Cell Motility, 2015, 36, 145-145.	0.9	0
41	Investigating the role of uncoupling of troponin I phosphorylation from changes in myofibrillar Ca ²⁺ sensitivity in the pathogenesis of cardiomyopathy. Frontiers in Physiology, 2014, 5, 315.	1.3	51
42	The Dilated Cardiomyopathy-Causing Mutation ACTC E361G in Cardiac Muscle Myofibrils Specifically Abolishes Modulation of Ca ²⁺ Regulation by Phosphorylation of Troponin I. Biophysical Journal, 2014, 107, 2369-2380.	0.2	22
43	Age-Related Cardiac Dysfunction in Transgenic Mice Carrying Actin E99K Mutation. Biophysical Journal, 2014, 106, 344a.	0.2	0
44	Mutation Update and Genotype-Phenotype Correlations of Novel and Previously Described Mutations in <i>TPM2</i> and <i>TPM3</i> Causing Congenital Myopathies. Human Mutation, 2014, 35, 779-790.	1.1	92
45	Effects of EMD57033 and EGCG on Modulation of Ca ²⁺ -Sensitivity by Pka Phosphorylation. Biophysical Journal, 2014, 106, 726a-727a.	0.2	1
46	Modulation of the Interaction between Troponin I N-Terminal Peptide and Troponin C by Phosphorylation Studied by Molecular Dynamics. Biophysical Journal, 2014, 106, 349a.	0.2	2
47	Dcm-Causing Mutation E361G in Actin Uncouples Myofibril Ca ²⁺ Sensitivity from Protein Phosphorylation. Biophysical Journal, 2014, 106, 774a-775a.	0.2	0
48	Skeletal muscle myopathy mutations at the actin tropomyosin interface that cause gain- or loss-of-function. Journal of Muscle Research and Cell Motility, 2013, 34, 165-169.	0.9	27
49	Tropomyosin isoform expression and phosphorylation in the human heart in health and disease. Journal of Muscle Research and Cell Motility, 2013, 34, 189-197.	0.9	25
50	DCM-Causing Mutation E361G in Actin Slows Myofibril Relaxation Kinetics and Uncouples Myofibril Ca ²⁺ Sensitivity from Protein Phosphorylation. Biophysical Journal, 2013, 104, 312a.	0.2	3
51	Familial dilated cardiomyopathy mutations uncouple troponin I phosphorylation from changes in myofibrillar Ca ²⁺ sensitivity. Cardiovascular Research, 2013, 99, 65-73.	1.8	68
52	Mutations in repeating structural motifs of tropomyosin cause gain of function in skeletal muscle myopathy patients. Human Molecular Genetics, 2013, 22, 4978-4987.	1.4	75
53	Introducing a special edition of the Journal of Muscle Research and Cell Motility on tropomyosin: form and function. Journal of Muscle Research and Cell Motility, 2013, 34, 151-153.	0.9	7
54	GSK3 ^β Phosphorylates Newly Identified Site in the Proline-Alanine-Rich Region of Cardiac Myosin-Binding Protein C and Alters Cross-Bridge Cycling Kinetics in Human. Circulation Research, 2013, 112, 633-639.	2.0	48

#	ARTICLE	IF	CITATIONS
55	Using FRET to Characterize the Actomyosin Complex in Cardiac Muscle. <i>Biophysical Journal</i> , 2013, 104, 16a.	0.2	0
56	There is a Limit to the Changes in Myofilament Ca ²⁺ -Sensitivity due to Myopathies. <i>Biophysical Journal</i> , 2013, 104, 312a.	0.2	0
57	A Repeating Structural Motif in Tropomyosin that is Responsible for Multiple Gain of Function Skeletal Myopathy Mutations. <i>Biophysical Journal</i> , 2013, 104, 646a-647a.	0.2	3
58	Myofibrillar Ca ²⁺ sensitivity is uncoupled from troponin I phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin T. <i>Cardiovascular Research</i> , 2013, 97, 500-508.	1.8	34
59	Mechanical and energetic properties of papillary muscle from <i>ACTC</i> ^{E99K} transgenic mouse models of hypertrophic cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 304, H1513-H1524.	1.5	25
60	Z-band Alternatively Spliced PDZ Motif Protein (ZASP) Is the Major O-Linked β -N-Acetylglucosamine-substituted Protein in Human Heart Myofibrils. <i>Journal of Biological Chemistry</i> , 2013, 288, 4891-4898.	1.6	12
61	Myosin Regulatory Light Chain (RLC) Phosphorylation Change as a Modulator of Cardiac Muscle Contraction in Disease. <i>Journal of Biological Chemistry</i> , 2013, 288, 13446-13454.	1.6	63
62	Atomic model of the human cardiac muscle myosin filament. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 318-323.	3.3	153
63	Abnormal actin binding of aberrant β -tropomyosins is a molecular cause of muscle weakness in <i>TPM2</i> -related nemaline and cap myopathy. <i>Biochemical Journal</i> , 2012, 442, 231-239.	1.7	48
64	The flexibility of two tropomyosin mutants, D175N and E180G, that cause hypertrophic cardiomyopathy. <i>Biochemical and Biophysical Research Communications</i> , 2012, 424, 493-496.	1.0	43
65	How do MYBPC3 mutations cause hypertrophic cardiomyopathy?. <i>Journal of Muscle Research and Cell Motility</i> , 2012, 33, 75-80.	0.9	93
66	Introducing a series of topical special issues of the <i>Journal of Muscle Research and Cell Motility</i> . <i>Journal of Muscle Research and Cell Motility</i> , 2012, 33, 1-3.	0.9	0
67	How Do Mutations in Contractile Proteins Cause the Primary Familial Cardiomyopathies?. <i>Journal of Cardiovascular Translational Research</i> , 2011, 4, 245-255.	1.1	106
68	Molecular Mechanism of the E99K Mutation in Cardiac Actin (<i>ACTC</i> Gene) That Causes Apical Hypertrophy in Man and Mouse. <i>Journal of Biological Chemistry</i> , 2011, 286, 27582-27593.	1.6	56
69	Investigation of changes in skeletal muscle β -actin expression in normal and pathological human and mouse hearts. <i>Journal of Muscle Research and Cell Motility</i> , 2010, 31, 207-214.	0.9	25
70	Investigation of a transgenic mouse model of familial dilated cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 380-389.	0.9	53
71	Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 737-745.	0.9	61
72	Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 1003-1011.	0.9	132

#	ARTICLE	IF	CITATIONS
73	Cardiac myocytes and the cardiac action potential. , 2010, , 2604-2618.		2
74	Evidence From Human Myectomy Samples That <i>MYBPC3</i> Mutations Cause Hypertrophic Cardiomyopathy Through Haploinsufficiency. <i>Circulation Research</i> , 2009, 105, 219-222.	2.0	210
75	Functional Analysis of a Unique Troponin C Mutation, GLY159ASP, that Causes Familial Dilated Cardiomyopathy, Studied in Explant Heart Muscle. <i>Circulation: Heart Failure</i> , 2009, 2, 456-464.	1.6	46
76	Direct visualisation and kinetic analysis of normal and nemaline myopathy actin polymerisation using total internal reflection microscopy. <i>Journal of Muscle Research and Cell Motility</i> , 2009, 30, 85-92.	0.9	9
77	Back to the future: new techniques show that forgotten phosphorylation sites are present in contractile proteins of the heart whilst intensively studied sites appear to be absent. <i>Journal of Muscle Research and Cell Motility</i> , 2009, 30, 93-95.	0.9	16
78	The use of phosphate-affinity SDS-PAGE to measure the cardiac troponin I phosphorylation site distribution in human heart muscle. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1371-1382.	0.8	58
79	Genotype-phenotype correlations in ACTA1 mutations that cause congenital myopathies. <i>Neuromuscular Disorders</i> , 2009, 19, 6-16.	0.3	87
80	Analysis of Cardiac Myofibrillar Troponin I Phosphorylation in Normal and Failing Human Hearts Using Phos-Tags. <i>Biophysical Journal</i> , 2009, 96, 501a.	0.2	2
81	Mouse HCM Model Expressing E99K ACTC Mutation Reproduces Phenotypes As Found In Human Patients. <i>Biophysical Journal</i> , 2009, 96, 499a-500a.	0.2	1
82	Direct Evidence In Man For Haploinsufficiency As The Mechanism Of Action Of Myosin-binding Protein C Mutations That Cause Hypertrophic Cardiomyopathy. <i>Biophysical Journal</i> , 2009, 96, 371a.	0.2	0
83	Myofilament dysfunction in cardiac disease from mice to men. <i>Journal of Muscle Research and Cell Motility</i> , 2008, 29, 189-201.	0.9	67
84	From genotype to phenotype: a longitudinal study of a patient with hypertrophic cardiomyopathy due to a mutation in the MYBPC3 gene. <i>Journal of Muscle Research and Cell Motility</i> , 2008, 29, 239-246.	0.9	28
85	How does genotype define phenotype? Microphysiology of a tropomyosin mutation <i>in situ</i> shows the limitations of reductionism. <i>Journal of Physiology</i> , 2008, 586, 2821-2821.	1.3	2
86	Cellular dysfunction and altered contractile protein post-translational modification in hypertrophic cardiomyopathy septal tissue. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 44, 746.	0.9	2
87	Myosin binding protein C phosphorylation in normal, hypertrophic and failing human heart muscle. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 209-216.	0.9	97
88	Troponin phosphorylation and myofilament Ca ²⁺ -sensitivity in heart failure: Increased or decreased?. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 45, 603-607.	0.9	69
89	Role of Caldesmon in the Ca ²⁺ Regulation of Smooth Muscle Thin Filaments. <i>Journal of Biological Chemistry</i> , 2008, 283, 47-56.	1.6	18
90	The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy. <i>Cardiovascular Research</i> , 2008, 79, 481-491.	1.8	41

#	ARTICLE	IF	CITATIONS
91	Alpha-cardiac actin mutations produce atrial septal defects. <i>Human Molecular Genetics</i> , 2008, 17, 256-265.	1.4	128
92	The Effect of Mutations in Î±-Tropomyosin (E40K and E54K) That Cause Familial Dilated Cardiomyopathy on the Regulatory Mechanism of Cardiac Muscle Thin Filaments. <i>Journal of Biological Chemistry</i> , 2007, 282, 13487-13497.	1.6	65
93	Troponin phosphorylation and regulatory function in human heart muscle: Dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2007, 42, 247-259.	0.9	162
94	The pathogenesis of ACTA1-related congenital fiber type disproportion. <i>Annals of Neurology</i> , 2007, 61, 552-561.	2.8	63
95	Effect of mutations in the Î²5-Î²7 loop on the structure and properties of human small heat shock protein HSP22 (HspB8, H11). <i>FEBS Journal</i> , 2007, 274, 5628-5642.	2.2	31
96	Small heat shock protein Hsp20 (HspB6) as a partner of 14-3-3Î³. <i>Molecular and Cellular Biochemistry</i> , 2007, 295, 9-17.	1.4	71
97	Structure and properties of K141E mutant of small heat shock protein HSP22 (HspB8, H11) that is expressed in human neuromuscular disorders. <i>Archives of Biochemistry and Biophysics</i> , 2006, 454, 32-41.	1.4	40
98	Evidence for reduced troponin I phosphorylation and altered troponin function in patients with hypertrophic obstructive cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 40, 939.	0.9	2
99	Fatal hypertrophic cardiomyopathy and nemaline myopathy associated with ACTA1 K336E mutation. <i>Neuromuscular Disorders</i> , 2006, 16, 548-552.	0.3	83
100	Dilated Cardiomyopathy Mutations in Three Thin Filament Regulatory Proteins Result in a Common Functional Phenotype. <i>Journal of Biological Chemistry</i> , 2005, 280, 28498-28506.	1.6	133
101	Functional characterisation of a mutant actin (Met132Val) from a patient with nemaline myopathy. <i>Neuromuscular Disorders</i> , 2004, 14, 167-174.	0.3	24
102	Random walks with thin filaments: application of in vitro motility assay to the study of actomyosin regulation. <i>Journal of Muscle Research and Cell Motility</i> , 2003, 24, 149-156.	0.9	18
103	Modulation of Thin Filament Activation by Breakdown or Isoform Switching of Thin Filament Proteins. <i>Circulation Research</i> , 2003, 93, 1170-1178.	2.0	81
104	Alterations in Thin Filament Regulation Induced by a Human Cardiac Troponin T Mutant That Causes Dilated Cardiomyopathy Are Distinct from Those Induced by Troponin T Mutants That Cause Hypertrophic Cardiomyopathy. <i>Journal of Biological Chemistry</i> , 2002, 277, 40710-40716.	1.6	125
105	Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility. <i>Biochemical Journal</i> , 2002, 362, 443-451.	1.7	30
106	In vitro Motility Analysis of Thin Filaments from Failing and Non-failing Human Heart: Troponin from Failing Human Hearts Induces Slower Filament Sliding and Higher Ca ²⁺ Sensitivity. <i>Journal of Molecular and Cellular Cardiology</i> , 2002, 34, 469-482.	0.9	37
107	Cardiac and skeletal myopathies: can genotype explain phenotype?. , 2001, 22, 1-4.		20
108	A simple method for measuring the relative force exerted by myosin on actin filaments in the in vitro motility assay: evidence that tropomyosin and troponin increase force in single thin filaments. <i>Biochemical Journal</i> , 2000, 350, 693.	1.7	24

#	ARTICLE	IF	CITATIONS
109	A simple method for measuring the relative force exerted by myosin on actin filaments in the in vitro motility assay: evidence that tropomyosin and troponin increase force in single thin filaments. <i>Biochemical Journal</i> , 2000, 350, 693-699.	1.7	66
110	A novel Ca ²⁺ binding protein associated with caldesmon in Ca ²⁺ -regulated smooth muscle thin filaments: evidence for a structurally altered form of calmodulin. <i>Journal of Muscle Research and Cell Motility</i> , 2000, 21, 537-549.	0.9	14
111	Investigation of a Truncated Cardiac Troponin T That Causes Familial Hypertrophic Cardiomyopathy. <i>Circulation Research</i> , 2000, 86, 1146-1152.	2.0	75
112	Effect of Hypertrophic Cardiomyopathy Mutations in Human Cardiac Muscle β -tropomyosin (Asp175Asn) Tj ETQq0 0 0 rgBT /Overlock Motility Assay. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 1489-1498.	0.9	67
113	Evidence against the regulation of caldesmon inhibitory activity by p42/p44erkmitogen-activated protein kinase in vitro and demonstration of another caldesmon kinase in intact gizzard smooth muscle. <i>FEBS Letters</i> , 1999, 452, 254-258.	1.3	26
114	Tropomyosin and Troponin Regulation of Wild Type and E93K Mutant Actin Filaments from Drosophila Flight Muscle. <i>Journal of Biological Chemistry</i> , 1998, 273, 15016-15021.	1.6	48
115	A simple method for automatic tracking of actin filaments in the motility assay. <i>Journal of Muscle Research and Cell Motility</i> , 1996, 17, 497-506.	0.9	51
116	In Vitro Motility Analysis of Actin-Tropomyosin Regulation by Troponin and Calcium. <i>Journal of Biological Chemistry</i> , 1995, 270, 7836-7841.	1.6	97
117	Localization of phospholipid-binding sites of caldesmon. <i>FEBS Letters</i> , 1994, 342, 176-180.	1.3	10
118	The functional effects of mutations Thr673 \rightarrow Asp and Ser702 \rightarrow Asp at the Pro-directed kinase phosphorylation sites in the C-terminus of chicken gizzard caldesmon. <i>FEBS Letters</i> , 1993, 327, 85-89.	1.3	29
119	Identification of casein kinase II as a major endogeneous caldesmon kinase in sheep aorta smooth muscle. <i>FEBS Letters</i> , 1993, 334, 18-22.	1.3	15
120	Phosphorylation of vascular smooth muscle caldesmon by endogenous kinase. <i>FEBS Letters</i> , 1992, 305, 192-196.	1.3	14
121	Purification and properties of Ca ²⁺ -regulated thin filaments and F-actin from sheep aorta smooth muscle. <i>Journal of Muscle Research and Cell Motility</i> , 1984, 5, 559-575.	0.9	97